OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
September 09, 2021
Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
August 26, 2021
Ophthalmologists face challenges of drug delivery for retinal diseases.
August 17, 2021
Visual benefit is not seen during first 2 years of Protocol W study.
August 11, 2021
Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.
July 20, 2021
Dual imaging may reduce costs, unnecessary referrals, telehealth study results show.
July 15, 2021
Promoting Tie2 signaling activity may complement inhibition of VEGF in addressing pathology in disease states characterized by angiogenesis, vascular permeability, and inflammation.
June 24, 2021
In a study, a single intravitreal injection of ADVM-022 had a 99% reduction in the mean annualized frequency of anti-VEGF injections.
June 23, 2021
Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.
June 21, 2021
In endophthalmitis, the systemic anti-infective treatment specific to the infectious agent should always be used.
June 18, 2021
According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.